Free companion page

Companion page: How to Read a Clinical Trial Agreement

Free to print: Appendix B: The Reading Checklist: Forty Questions for Any Site Contract, from How to Read a Clinical Trial Agreement.

This page is free and needs no sign-up. It reproduces material from How to Read a Clinical Trial Agreement by Julian R. Sterling so you can print it or keep it open while you work.

To print it, use your browser's print button. Figures are as stated in the book; check the official source before relying on any of them.

Appendix B: The Reading Checklist: Forty Questions for Any Site Contract

Read a site contract with these forty questions beside it. Each question has one line and one sentence on why it matters, with the chapter that explains the rule. The case figures are those of Veldtman and Penhallow, and they are teaching assumptions, not market figures. Chapter 12 shows all the questions answered on one complete file.

Parties and Documents

  1. Who signs the agreement, and does each legal name match the entity that will perform the work? A wrong name can leave a promise with nobody who can be held to it, and the signature block is the first place a mismatch shows (Chapter 2).

  2. In what capacity does the principal investigator sign: as a party, or only to acknowledge the terms? In the case the principal investigator signs to acknowledge, and the reader should know whether that signature creates duties of its own (Chapter 2).

  3. Is the CRO a party, or only the sponsor's agent, and for which tasks? In the case Orvanta does not sign and acts as Veldtman's agent for monitoring and site payments, so the reader must know whose promise a payment is (Chapter 2).

  4. What is attached to the agreement, and is each attachment the final version? The case attaches the protocol, the budget and payment schedule and the subject injury terms, and a stale budget attached to a signed agreement quietly becomes the price (Chapter 2).

  5. Which document prevails if two conflict? In the case the agreement prevails on legal and payment terms and the protocol on the medical conduct of the study, a split that works only if the agreement says so (Chapter 2).

  6. What does a late signature cost, and who carries it? In the case the draft went out in Month 1 for a Month 3 target and was signed in Month 5; Veldtman's trial-wide running cost is $350,000 a month, so a late site that pushed the last participant in back by 2 months would cost it $700,000 (Chapter 1).

Regulatory Frame

  1. Does the agreement require the study to follow good clinical practice, and does it name the guideline it means? A named standard gives both sides a yardstick when a visit or a record is questioned (Chapter 3).

  2. Which IRB reviews the study, and is its approval a condition for starting and for continuing? In the case Penhallow's own IRB approves in Month 4, and the first participant is enrolled in Month 7 (Chapter 3).

  3. Does the agreement require informed consent before any study procedure, and who supplies and approves the form? Consent is the participant's protection and the base for any later use of samples and data (Chapter 3).

  4. Does the agreement address the investigator's signed statement of commitments, Form FDA 1572, and how changes in the study team are reported to the sponsor? The statement is a federal commitment that sits beside the contract, and the two should not contradict each other (Chapter 3).

Budget and Payments

  1. What is the per-participant fee, and how is it split across visits? In the case $18,432 per completed participant is split by visit, which fixes what is owed if a participant stops early (Chapter 4).

  2. What overhead rate sits inside the fee, and is it applied to every line? In the case the parties agreed on 28 percent after an ask of 30 percent and an offer of 25 percent, and the rate decides how much of the site's fixed cost the fee covers (Chapter 4).

  3. What is paid at start-up, and what is refundable? In the case the start-up fee is $25,000, non-refundable and due within 30 days of signature, while IRB fees are invoiced at cost, and the reader should compare the fee with the real cost of opening the site (Chapter 4).

  4. How are screen failures paid, and is there a ceiling? In the case a screen failure is paid at the visit 1 fee up to one for every four enrolled, so 10 are paid and 6 are not (Chapter 4).

  5. Which costs are passed through at cost, and what proof of cost is required? In the case imaging, the close-out fee and the archiving fee sit outside the per-participant fee, and an unclear pass-through line becomes a dispute at the end (Chapter 4).

  6. How much of each payment is held back, until what event, and who decides that the data are clean? In the case 10 percent is held until database lock, $73,728 for 40 participants, invoiced in Month 31 and paid in Month 32 (Chapter 4).

  7. How soon are invoices paid, and what happens to a disputed line? In the case Orvanta pays quarterly invoices within 45 days, and a good clause lets the undisputed part be paid while the rest is settled (Chapter 4).

  8. At what enrollment does the site break even? In the case it takes 24 completed participants at 28 percent overhead, so a slow-enrolling site can lose money on a contract that looks generous (Chapter 4).

Subject Injury, Indemnity and Insurance

  1. Which injuries does the sponsor pay for? In the case an injury caused by VLD-207 or by a procedure the protocol requires and performed as written, so the wording of the cause decides every claim (Chapter 5).

  2. Does the sponsor pay first, or must the participant's insurer be billed first? In the case Veldtman pays without first billing the insurer, and a reader should see how that choice changes who holds the bill (Chapter 5).

  3. What is excluded? In the case Penhallow's negligence, a failure to follow the protocol, the natural progression of the disease and standard-of-care treatment, and each exclusion should be read against the facts of a real injury (Chapter 5).

  4. Does the agreement say who handles the Medicare side for an injured participant who is a Medicare beneficiary? A silent agreement leaves the reporting and payer questions to be argued after the injury (Chapter 5).

  5. Who defends and indemnifies whom, and what are the carve-outs? In the case Veldtman defends and indemnifies Penhallow, its staff and its IRB unless the claim comes from Penhallow's negligence or a departure from the protocol (Chapter 6).

  6. What insurance does each party carry, and does it fit the promises made? In the case Veldtman carries $5,000,000 per occurrence and $10,000,000 in the aggregate, Penhallow $2,000,000 and $5,000,000, and an indemnity is only as good as the cover behind it (Chapter 6).

  7. Is there a cap on liability, and what does it leave out? In the case Penhallow's draft caps its liability to Veldtman at $250,000, and lost profits and consequential damages are excluded except under the indemnities (Chapter 6).

Data, Samples and Inventions

  1. Who owns the study data, and what may the institution do with it afterward? In the case Veldtman owns it, and Penhallow keeps its medical records and may use the data for treatment and internal non-commercial research after publication (Chapter 7).

  2. How fast must data be entered and queries answered? In the case within 5 business days of each visit and within 10 business days for queries, and these are the dates a monitor will hold the site to (Chapter 7).

  3. What may be done with research samples, and does the consent cover future research? In the case 31 of 40 participants sign the optional consent, so only their leftover samples may be kept after the study (Chapter 7).

  4. Who owns inventions, and is there an option to license? In the case inventions about VLD-207 or made with Veldtman's confidential information belong to Veldtman, and Veldtman has a 90-day option on the rest (Chapter 7).

Publication and Confidentiality

  1. When may the institution publish its own results? In the case from the earlier of the multicenter paper and 18 months after primary completion, which is Month 38, and the order of papers is a business term as much as an academic one (Chapter 8).

  2. How long is the sponsor's review, and can it ask for a patent delay? In the case Veldtman reviews for 60 days and asks for a further 60 days, so Penhallow submits in Month 43 (Chapter 8).

  3. What counts as confidential information, and for how long is it protected? In the case confidentiality lasts 5 years after the study ends, and a reader should check that it does not swallow the right to publish (Chapter 8).

  4. Who registers the trial on ClinicalTrials.gov and posts the results, and by when? In the case Veldtman registers in Month 5 and posts results in Month 40, and the agreement should say that the site must not do it a second time (Chapter 8).

Obligations and Records

  1. What must the investigator do under the protocol, and is the delegation of tasks recorded? A signed delegation log shows who did what, which matters when a record is questioned (Chapter 9).

  2. How often is the site monitored, and what access do audits and inspections get? In the case Orvanta's monitor visits every 8 weeks from Month 7 to Month 29, 12 visits in all (Chapter 9).

  3. How long must records be kept, and who pays for storage? In the case the longer of the regulatory period and 15 years after the study ends, with an archiving fee of $2,500 (Chapter 9).

Termination and Close-Out

  1. Who may end or suspend the study, on what notice and for what reasons? Convenience, safety, breach and loss of the investigator are the families Chapter 10 reads, and each should have a clear route and a clear payment result (Chapter 10).

  2. What is owed at the end, and which clauses survive? In the termination test, Veldtman stops the trial in Month 18 and the termination clause settles $354,200 of visit fees and wind-down costs, while in the case the close-out visit takes place in Month 33; the reader should check that the survival clause names confidentiality, indemnity, subject injury, publication, records and payment (Chapter 10).

Privacy and Transparency

  1. Does a HIPAA authorization let the institution share participants' health information with the sponsor and the CRO, and who keeps the signed forms? Without it, the data flow in the agreement may have no lawful base (Chapter 11).

  2. Are financial disclosure and payment reporting covered? In the case Veldtman pays Penhallow's principal investigator $30,000 of advisory board fees in Month 12, and the agreement should say who collects the disclosure and who reports the payment (Chapter 11).